Atea Pharmaceuticals Inc (NASDAQ: AVIR) on Monday, plunged -3.41% from the previous trading day, before settling in for the closing price of $3.52. Within the past 52 weeks, AVIR’s price has moved between $2.75 and $4.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 130.62% over the last five years. The company achieved an average annual earnings per share of -10.74%. With a float of $74.01 million, this company’s outstanding shares have now reached $84.46 million.
The firm has a total of 75 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atea Pharmaceuticals Inc (AVIR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atea Pharmaceuticals Inc is 12.38%, while institutional ownership is 66.04%. The most recent insider transaction that took place on Dec 10 ’24, was worth 1,023,475. In this transaction Director of this company sold 359,606 shares at a rate of $2.85, taking the stock ownership to the 451,897 shares. Before that another transaction happened on Dec 10 ’24, when Company’s Lead Independent Director proposed sale 359,606 for $2.85, making the entire transaction worth $1,023,475.
Atea Pharmaceuticals Inc (AVIR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -10.74% per share during the next fiscal year.
Atea Pharmaceuticals Inc (NASDAQ: AVIR) Trading Performance Indicators
Atea Pharmaceuticals Inc (AVIR) is currently performing well based on its current performance indicators. A quick ratio of 19.33 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.07, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.58 in one year’s time.
Technical Analysis of Atea Pharmaceuticals Inc (AVIR)
Analysing the last 5-days average volume posted by the [Atea Pharmaceuticals Inc, AVIR], we can find that recorded value of 0.39 million was lower than the volume posted last year of 0.41 million. As of the previous 9 days, the stock’s Stochastic %D was 69.78%. Additionally, its Average True Range was 0.15.
During the past 100 days, Atea Pharmaceuticals Inc’s (AVIR) raw stochastic average was set at 46.59%, which indicates a significant decrease from 64.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 30.63% in the past 14 days, which was lower than the 44.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.27, while its 200-day Moving Average is $3.57. Now, the first resistance to watch is $3.49. This is followed by the second major resistance level at $3.58. The third major resistance level sits at $3.65. If the price goes on to break the first support level at $3.34, it is likely to go to the next support level at $3.27. Should the price break the second support level, the third support level stands at $3.18.
Atea Pharmaceuticals Inc (NASDAQ: AVIR) Key Stats
Market capitalization of the company is 287.17 million based on 84,463K outstanding shares. Right now, sales total 0 K and income totals -135,960 K. The company made 0 K in profit during its latest quarter, and -31,150 K in sales during its previous quarter.
